383 related articles for article (PubMed ID: 28668466)
21. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
Marrone A; Capoluongo N; D'Amore C; Pisaturo M; Esposito M; Guastafierro S; Siniscalchi I; Macera M; Boemio A; Onorato L; Rinaldi L; Minichini C; Adinolfi LE; Sagnelli E; Mastrullo L; Coppola N
J Viral Hepat; 2018 Feb; 25(2):198-204. PubMed ID: 29029365
[TBL] [Abstract][Full Text] [Related]
22. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review.
Gentile G; Antonelli G
Viruses; 2019 Nov; 11(11):. PubMed ID: 31717647
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study.
Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lau EHY; Cheung KS; Lie AKW; Lai CL; Kwong YL; Yuen MF
Hepatology; 2017 May; 65(5):1451-1461. PubMed ID: 28027590
[TBL] [Abstract][Full Text] [Related]
24. Determining Whether Prophylactic Antiviral Treatment Is Necessary in HBsAg-Negative/HBcAb-Positive Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Zhang A; Wu Y; Tan Y; Shi J; Zhao Y; Hu Y; Yu J; Zheng W; Lai X; Zhang M; Zhu Y; Ye Y; Huang Y; Fu S; Huang H; Luo Y
Biol Blood Marrow Transplant; 2020 May; 26(5):956-964. PubMed ID: 31962163
[TBL] [Abstract][Full Text] [Related]
25. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
Hsiao LT; Chiou TJ; Liu JH; Chu CJ; Lin YC; Chao TC; Wang WS; Yen CC; Yang MH; Tzeng CH; Chen PM
Biol Blood Marrow Transplant; 2006 Jan; 12(1):84-94. PubMed ID: 16399572
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
27. The difficulties of managing severe hepatitis B virus reactivation.
Roche B; Samuel D
Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
[TBL] [Abstract][Full Text] [Related]
28. A multicenter evaluation of hepatitis B reactivation with and without antiviral prophylaxis after kidney transplantation.
Shaikh SA; Kahn J; Aksentijevic A; Kawewat-Ho P; Bixby A; Rendulic T; Park JM
Transpl Infect Dis; 2022 Feb; 24(1):e13751. PubMed ID: 34725887
[TBL] [Abstract][Full Text] [Related]
29. HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea.
Jun CH; Kim BS; Oak CY; Lee DH; Cho E; Cho SB; Choi SK; Park CH; Joo YE; Lee JJ; Kim HJ
Hepatol Int; 2017 Jan; 11(1):87-95. PubMed ID: 27351765
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis B Virus Vaccination after Allogeneic Hematopoietic Cell Transplantation Prevents Post-Transplantation Hepatitis B Virus Reactivation.
Hammond SP; Ho VT; Marty FM
Transplant Cell Ther; 2022 Jul; 28(7):402.e1-402.e5. PubMed ID: 35413458
[TBL] [Abstract][Full Text] [Related]
31. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment.
Nakamoto S; Kanda T; Nakaseko C; Sakaida E; Ohwada C; Takeuchi M; Takeda Y; Mimura N; Iseki T; Wu S; Arai M; Imazeki F; Saito K; Shirasawa H; Yokosuka O
Int J Mol Sci; 2014 Nov; 15(11):21455-67. PubMed ID: 25421241
[TBL] [Abstract][Full Text] [Related]
32. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation.
Uhm JE; Kim K; Lim TK; Park BB; Park S; Hong YS; Lee SC; Hwang IG; Koh KC; Lee MH; Ahn JS; Kim WS; Jung CW; Kang WK
Biol Blood Marrow Transplant; 2007 Apr; 13(4):463-8. PubMed ID: 17382252
[TBL] [Abstract][Full Text] [Related]
33. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.
Fidan S; Capkın E; Arıca DA; Durak S; Okatan IE
Int J Rheum Dis; 2021 Feb; 24(2):254-259. PubMed ID: 33244900
[TBL] [Abstract][Full Text] [Related]
34. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy.
Francisci D; Falcinelli F; Schiaroli E; Capponi M; Belfiori B; Flenghi L; Baldelli F
Infection; 2010 Feb; 38(1):58-61. PubMed ID: 19904491
[TBL] [Abstract][Full Text] [Related]
35. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.
Lalazar G; Rund D; Shouval D
Br J Haematol; 2007 Mar; 136(5):699-712. PubMed ID: 17338776
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.
Hwang JP; Feld JJ; Hammond SP; Wang SH; Alston-Johnson DE; Cryer DR; Hershman DL; Loehrer AP; Sabichi AL; Symington BE; Terrault N; Wong ML; Somerfield MR; Artz AS
J Clin Oncol; 2020 Nov; 38(31):3698-3715. PubMed ID: 32716741
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update.
Hwang JP; Somerfield MR; Alston-Johnson DE; Cryer DR; Feld JJ; Kramer BS; Sabichi AL; Wong SL; Artz AS
J Clin Oncol; 2015 Jul; 33(19):2212-20. PubMed ID: 25964247
[TBL] [Abstract][Full Text] [Related]
38. Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection.
Liu S; He Z; Wu W; Jin H; Cui Y
Clin Rheumatol; 2023 Sep; 42(9):2369-2376. PubMed ID: 37219751
[TBL] [Abstract][Full Text] [Related]
39. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
[TBL] [Abstract][Full Text] [Related]
40. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study.
Tsai YF; Yang CI; Du JS; Lin MH; Tang SH; Wang HC; Cho SF; Liu YC; Su YC; Dai CY; Hsiao HH
PeerJ; 2019; 7():e7481. PubMed ID: 31565551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
